Sorrento Therapeutics Inc on Friday partnered with New York City's Mount Sinai Health System to develop an antibody cocktail to potentially treat or prevent covid-19, with the aim of starting human trials in the third quarter.
There are currently no treatments or vaccines approved for the coronavirus and several drugmakers have been rushing to develop new treatments or repurpose existing drugs to treat patients.
Regeneron currently leads the effort to develop an antibody cocktail and has said its experimental therapy may be available for use as early as the end of summer as it ramps up efforts to start human trials in June.